The Vicious Cycle of BRASH Syndrome: A Case Report and a Brief Review of Literature
Published: 2023-09-26
Page: 136-139
Issue: 2023 - Volume 5 [Issue 1]
Charif H. *
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Patrick M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Njie M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Jama D.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
B. E. Ovaga
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco.
Haboub M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Arous S.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Bennouna E. M.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Drighil A.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Habbal R.
Department of Cardiology, Ibn Rochd University Hospital, Casablanca, Morocco and Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
BRASH syndrome is a medical condition characterized by the combination of bradycardia (a slow heart rate) and shock in individuals with renal failure, a history of taking atrioventricular (AV) nodal blocking medications, and hyperkalemia (elevated levels of potassium in the blood). This syndrome typically occurs in elderly individuals who have compromised kidney function and a history of regularly using AV nodal blocking medications [1]. Major risk factors for BRASH syndrome include hypovolemia (low blood volume) and worsening kidney function. It's important to recognize that these manifestations should be considered as part of a syndrome rather than isolated findings, as they are interconnected and have synergistic effects on each other. These underlying physiological processes create a harmful cycle of bradycardia and reduced cardiac output, leading to organ dysfunction, including renal failure with hyperkalemia, which in turn exacerbates the bradycardia. BRASH syndrome is associated with significant morbidity and mortality [2].Typically, the treatment approach for BRASH syndrome involves increasing renal blood flow by enhancing cardiac output through the administration of catecholamines. In rare cases, interventions such as intralipid emulsion and continuous renal replacement therapy (CRRT) may be necessary, depending on the specific circumstances. Early recognition of BRASH syndrome is crucial, as it can help prevent diagnostic delays and reduce mortality rates. In the case presented here, the patient's medical history provided important clues that led to the early identification and aggressive treatment of BRASH syndrome. This timely intervention prevented the onset of shock, reduced morbidity, and improved overall outcomes.
Keywords: Atrioventricular node blocker, bradycardia, BRASH, hyperkalemia, renal failure, shock
How to Cite
Downloads
References
Farkas J. PulmCrit- BRASH syndrome: Bradycardia, Renal failure, Av blocker, Shock. Hyperkalemia. February 15; 2016. Available:https://emcrit.org/pulmcrit/brash-syndrome-bradycardia-renal-failure-av-blocker-shock-hyperkalemia/
Calvin J. Tan BS. BRASH Syndrome: Profound Bradycardia in the Setting of Mild Hyperkalemia State University of New York – Downstate, College of Medicine; Kings County Hospital Center. Available:https://www.emra.org/siteassets/emra/be-involved/events--activities/casecon/2018-posters/group-2/calvin_tan_final_poster.pdf
Farkas JD, Long B, Koyfman A, Menson K. BRASH Syndrome: Bradycardia, Renal Failure, AV Blockade, Shock, and Hyperkalemia. J Emerg Med. 2020 Aug; 59(2):216-223. DOI:10.1016/j.jemermed.2020.05.001. Epub 2020 Jun 18.
PMID: 32565167. Available:https://pubmed.ncbi.nlm.nih.gov/32565167/
Sattar Y, Bareeqa SB, Rauf H, Ullah W, Alraies MC. Bradycardia, Renal Failure, Atrioventricular-nodal Blocker, Shock, and Hyperkalemia Syndrome Diagnosis and Literature Review. Cureus. 2020 Feb 13; 12(2):e6985.
DOI: 10.7759/cureus.6985. PMID: 32201662; PMCID: PMC7075507. Available:https://pubmed.ncbi.nlm.nih.gov/32201662/
Srivastava S, Kemnic T, Hildebrandt KR. BRASH syndrome. BMJ Case Rep. Feb 23 2020;13(2):e233825.
DOI: 10.1136/bcr-2019-233825. PMID: 32094236; PMCID: PMC7046371. Available:https://pubmed.ncbi.nlm.nih.gov/32094236/
Zhou M and AH Khan, Bradycardia, Renal Failure, AV-Nodal Blockers, Shock, and Hyperkalemia (BRASH) - A New Clinical Syndrome, in American Thoracic Society 2018 International Conference.: San Diego, CA. 2018:A3467-A3467.
Available:https://pubmed.ncbi.nlm.nih.gov/35475060/
Nathani A, Lingamaneni P, Radigan KA. Brash Syndrome: An Emerging Clinical Entity.A43. Critical case reports: Toxicology and poisonings. American Journal of Respiratory and Critical Care Medicine. 2020:201A1666
Available:https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1666 [in A43. l.c. p. A1666-A1666]
Saini T, Reny J, Hennawi HA, Cox A, Janga C, DeLiana D, McCaffrey J. The vicious cycle of BRASH syndrome: A case report. Glob Cardiol Sci Pract. Jan 30 2023;2023(1):e202302. DOI: 10.21542/gcsp.2023.2. PMID: 36890842; PMCID: PMC9988297. Available:https://pubmed.ncbi.nlm.nih.gov/36890842/
Shah P, Silangruz K, Lee E, Nishimura Y. Two Cases of BRASH Syndrome: A Diagnostic Challenge. Eur J Case Rep Intern Med. 2022 Apr 8;9(4):003314. DOI: 10.12890/2022_003314. PMID: 35520368; PMCID: PMC9067425.